Targeted Drug Cuts Lung Cancer Recurrence Risk by 83% After Surgery

A landmark phase III clinical trial has established a new standard of care for a rare but significant subset of lung cancer patients, showing that a targeted oral drug can dramatically reduce the chance of cancer returning after what was intended to be curative treatment.

The LIBRETTO-432 trial enrolled 151 patients with RET fusion-positive non-small-cell lung cancer (NSCLC) who had undergone surgery or radiation for stage IB-IIIA disease. Participants were randomized to receive either selpercatinib or a placebo for three years. At the two-year mark, 92% of those on selpercatinib remained event-free, compared to just 61% in the placebo group — a hazard ratio of 0.17, meaning an 83% reduction in recurrence risk. All three deaths from disease progression occurred in the placebo arm.

The findings were presented at the American Society of Clinical Oncology annual meeting and published simultaneously in the New England Journal of Medicine, lending them immediate scientific and clinical weight. Experts not involved in the trial called it groundbreaking and immediately practice-changing, noting it mirrors earlier successes with targeted therapies for EGFR- and ALK-driven lung cancers.

For health-conscious readers, the broader implication is profound: knowing your tumor's genetic profile at diagnosis is no longer optional — it is medically decisive. RET fusions affect 1-2% of NSCLC patients, disproportionately younger, never- or light-smokers. Without genetic screening, this group would miss a potentially curative adjuvant therapy.

Caveats include the trial's relatively small size (151 patients), driven by the rarity of RET fusions — nearly 3,500 were screened to find them. Longer follow-up is needed to confirm whether EFS improvements translate to overall survival benefits. Nevertheless, selpercatinib already holds FDA approval for advanced RET-positive cancers, giving this new indication strong regulatory footing.